Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the MRC Weatherall Institute of Molecular Medicine have recently discovered why a class of cancer drugs is beneficial only in a subset of patients. The results could pave the way for the future development of these drugs, known as PNP-inhibitors, as personalised medicines.

Digital illustration of a cancer cell and DNA strand

Similar stories

New study maps the development of the human intestine

MRC HIU RDM

Researchers in the Simmons lab chart the embryonic origins and appearance of diverse intestinal cellular compartments, with important implications for intestinal diseases.

MRC HIU appoints new Director

MRC HIU RDM

We are pleased to announce that Professor Alison Simmons has been appointed as the new Director of the MRC Human Immunology Unit.

Study uncovers how low blood iron diminishes immune response

MRC HIU NDM RDM

The Drakesmith group finds that low blood serum iron levels can inhibit T-cell and B-cell immune responses to vaccines and infections.